William C. Fairey
William C. Fairey has served on Mirum’s board of directors since 2021. Mr. Fairey brings nearly 30 years of experience building strong and scalable global commercial organizations. Most recently, Mr. Fairey served as executive vice president and chief commercial officer at MyoKardia where he built the commercial and portfolio strategy, established the company’s European headquarters, and was structuring the expansion in Latin America and Asia when the company was acquired by Bristol-Myers Squibb. Mr. Fairey held a similar role at ChemoCentryx, where, as chief operations officer, he was responsible for building out the initial commercial and medical teams. Prior to ChemoCentryx, he served in a number of roles at Actelion Pharmaceuticals, including president of the U.S. division. Before taking that role, Mr. Fairey developed Actelion’s Asia-Pacific business, creating new opportunities in China, Taiwan, and Southeast Asia, and chaired the board of directors for Actelion China. He was also president of Actelion Canada and vice president, sales and managed markets, one of the founding members of the U.S. executive team.
Mr. Fairey received his undergraduate degree from the University of Oregon and an M.B.A. from Saint Mary’s College.